Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibiotic Prophylaxis for HDR Brachytherapy in Prostate Cancer
NCT03862170Phase 3Terminated
- Sponsor
- Centre de recherche Charles-Le Moyne
- Start
- Feb 2015
- Primary completion
- Feb 2020
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cefazolin in urinary tract infection (UTI) (3 arms), sponsored by Centre de recherche Charles-Le Moyne. Primary endpoint: Symptomatic urinary infections post HDR brachytherapy at 6 months. Started Feb 2015; status: terminated.
02
Drugs
cefazolin
03
Conditions
urinary tract infection (UTI)
Beyond the preview
Go deeper on NCT03862170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03862170.